Siemens Healthineers will leverage its regional network and healthcare technology expertise to support the adoption of Aiforia's pathology tools.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.

NEW YORK – Becton Dickinson announced on Wednesday that its new human papillomavirus self-collection solution has received certification under Europe's In Vitro Diagnostic Regulation. The new ...

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

The firm's diagnostics revenues rose 4 percent to $2.46 billion, partially due to the growth of respiratory disease testing-related revenues from Cepheid.

The private equity firms expect to close the deal in the first half of 2026 with a valuation of up to $79 per share.

The company said that its low-cost, high-throughput four-plex test could help to identify type 1 diabetes patients sooner and inform treatments to delay progression.

Having expanded access to quantitative hemoglobin variant testing in 40 countries, Hemex is now also setting its sights on the US and Europe.